Opexa Therapeutics (OPXA) Tops Q1 EPS by 4c

Opexa Therapeutics (NASDAQ: OPXA) reported Q1 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $726.3 thousand versus the consensus estimate of $400 thousand.

Financial Guidance

Based on the current activities of the Company and projected burn, Opexa believes it has sufficient liquidity to support its current clinical activities for the Abili-T trial of Tcelna in SPMS, to continue planned preclinical development activities for OPX-212 in NMO, and for general operations to sustain the Company and support such activities through the first quarter of 2017. Opexa expects top-line data for the Abili-T trial to be available early in the fourth quarter of 2016, and thus believes it has sufficient resources to complete such trial.

For earnings history and earnings-related data on Opexa Therapeutics (OPXA) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• VNET Group (VNET) Misses Q2 EPS by 164c
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance